Toggle light / dark theme

Will implantable brain-computer interfaces soon benefit people with motor impairments?

A review published in Advanced Science highlights the evolution of research related to implantable brain-computer interfaces (iBCIs), which decode brain signals that are then translated into commands for external devices to potentially benefit individuals with impairments such as loss of limb function or speech.

A comprehensive systematic review identified 112 studies, nearly half of which have been published since 2020. Eighty iBCI participants were identified, mostly participating in studies concentrated in the United States, but with growing numbers of studies from Europe, China, and Australia.

The analysis revealed that iBCI technologies are being used to control devices such as robotic prosthetic limbs and consumer .

FDA grants orphan drug designation to UAB-developed gene therapy for ALS

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral Sclerosis (ALS) developed at the Universitat Autònoma de Barcelona and licensed to the U.S. company Klotho Neurosciences, Inc.

The drug uses a viral vector of the AAV (adeno-associated virus) type that expresses the secreted isoform of Klotho (s-KL) protein, with neuroregenerating, antioxidant and anti-inflammatory properties. In order to reach the neuromuscular junctions affected by the ALS disease, the vector acts under the control of a DNA sequence that regulates the expression of the protein specifically in the muscle (a muscle-specific promoter), so that therapeutic activity is directed towards the neuromuscular junctions. This innovative approach has shown very promising results in the most widely used mouse model for the preclinical study of ALS, delaying the onset of the disease, preserving neuromuscular function and extending survival.


The technological development was led by UAB researchers, with the involvement of the CIBER, ICREA and Vall d’Hebron Research Institute, co-owners of the intellectual property relating to the use of the Klotho protein and licensed to Klotho Neurosciences –a start-up company based on knowledge generated at UAB and listed on Nasdaq in 2023 (NASDAQ: KLTO)-. The technology was developed by the research groups of Assumpció Bosch and Miquel Chillón, both from the UAB Department of Biochemistry and Molecular Biology and the UAB Institut de Neurociències (INc-UAB). The research project also included the collaboration of the group led by Professor Xavier Navarro, researcher at the Institut de Neurociències and the UAB Department of Cellular Biology, Physiology and Immunology, and expert in neuroregeneration and motor neuron diseases.

“The orphan drug designation for the therapy we have developed acknowledges the relevance of treatments targeting muscle and neuromuscular junction as a strategy for ALS”, says Assumpció Bosch, principal investigator of the study. “To date, we have been able to demonstrate efficacy in a leading animal model for this pathology. We are now testing it in other ALS models to confirm that this therapeutic solution can be applied to the widest possible number of patients”, adds Sergi Verdés, postdoctoral researcher on the research team.

Receiving the orphan drug designation by the FDA underscores the potential of the treatment for the rare and severely disabling disease ALS, which affects around 65,000 people in Europe and for which there is no effective treatment. This recognition offers advantages such as seven years of exclusivity for the drug in the U.S. market, fee waivers and tax incentives for clinical trials.

This Common Blood Pressure Drug Extends Lifespan, Slows Aging in Animals

The hypertension drug rilmenidine has been shown to slow down aging in worms, an effect that in humans could hypothetically help us live longer and keep us healthier in our latter years.

Previous research has shown rilmenidine mimics the effects of caloric restriction on a cellular level. Reducing available energy while maintaining nutrition within the body has been shown to extend lifespans in several animal models.

Whether this translates to human biology, or is a potential risk to our health, is a topic of ongoing debate. Finding ways to achieve the same benefits without the costs of extreme calorie cutting could lead to new ways to improve health in old age.

Stem cell transplant without toxic preparation successfully treats genetic disease

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a Phase I clinical trial has shown.

While the researchers tested the protocol on patients with Fanconi anemia, a genetic disease that makes standard stem cell transplant extremely risky, they expect it may also work for patients with other genetic diseases that require stem cell transplants.

“We were able to treat these really fragile patients with a new, innovative regimen that allowed us to reduce the toxicity of the stem cell transplant protocol,” said the study’s co-senior author, Agnieszka Czechowicz, MD, Ph.D., assistant professor of pediatrics.

Fusion Future Ignited: New Ultra-Precise Laser Technology Could Finally Make Net-Energy Devices a Scalable Global Reality

IN A NUTSHELL 🌟 Coherent Corp. unveils a powerful new laser to accelerate the production of high-temperature superconducting tape. ⚡ The LEAP 600C laser utilizes Pulsed Laser Deposition, offering twice the power and longer maintenance intervals. 🔬 HTS tape is essential for fusion energy and various technologies, including MRI machines and power grids. 🌍 This

Finding Human Brain Genes in Duplicated DNA

“Historically, this has been a very challenging problem. People don’t know where to start,” said senior author Megan Dennis, associate director of genomics at the UC Davis Genome Center and associate professor in the Department of Biochemistry and Molecular Medicine and MIND Institute at the University of California, Davis.

In 2022, Dennis was a co-author on a paper describing the first sequence of a complete human genome, known as the ‘telomere to telomere’ reference genome. This reference genome includes the difficult regions that had been left out of the first draft published in 2001 and is now being used to make new discoveries.

Dennis and colleagues used the telomere-to-telomere human genome to identify duplicated genes. Then, they sorted those for genes that are: expressed in the brain; found in all humans, based on sequences from the 1,000 Genomes Project; and conserved, meaning that they did not show much variation among individuals.

They came out with about 250 candidate gene families. Of these, they picked some for further study in an animal model, the zebrafish. By both deleting genes and introducing human-duplicated genes into zebrafish, they showed that at least two of these genes might contribute to features of the human brain: one called GPR89B led to slightly bigger brain size, and another, FRMPD2B, led to altered synapse signaling.

“It’s pretty cool to think that you can use fish to test a human brain trait,” Dennis said.

The dataset in the Cell paper is intended to be a resource for the scientific community, Dennis said. It should make it easier to screen duplicated regions for mutations, for example related to language deficits or autism, that have been missed in previous genome-wide screening.

“It opens up new areas,” Dennis said.

How pH impacts the immune system

Extrachromosomal DNA in cancer.

This review discusses open questions on the evolutionary role of extrachromosomal DNA (ecDNA) in tumor development, including tumorigenesis and metastatic seeding.

The author discuss the mutational landscape on ecDNA, the dynamic ecDNA genotype– phenotype map, the structural evolution of ecDNA, and how knowledge of tissue-specific ecDNA evolutionary paths can be leveraged to deliver more effective clinical treatment.

They also describe how evolutionary theoretical modeling will be instrumental in advancing new research in the field, and we explore how modeling has contributed to our understanding of the evolutionary principles governing ecDNA dynamics.

https://www.cell.com/trends/cancer/fulltext/S2405-8033(25)00146-3 https://sciencemission.com/Extrachromosomal-DNA


Cancers are complex, diverse, and elusive, with extrachromosomal DNA (ecDNA) recently emerging as a crucial player in driving the evolution of about 20% of all tumors. In this review we discuss open questions concerning the evolutionary role of ecDNA in tumor development, including tumorigenesis and metastatic seeding, the mutational landscape on ecDNA, the dynamic ecDNA genotype–phenotype map, the structural evolution of ecDNA, and how knowledge of tissue-specific ecDNA evolutionary paths can be leveraged to deliver more effective clinical treatment. Looking forward, evolutionary theoretical modeling will be instrumental in advancing new research in the field, and we explore how modeling has contributed to our understanding of the evolutionary principles governing ecDNA dynamics.

New insights from the 1000 Genomes Project provide most complete view to date of human genetic variation

Completed in 2003, the Human Genome Project gave us the first sequence of the human genome, albeit based on DNA from a small handful of people. Building upon its success, the 1000 Genomes Project was conceived in 2007. The project began with the ambitious aim of sequencing 1,000 human genomes and exceeded it, publishing results gleaned from over 2,500 individuals of varying ancestries in 2015.

Printing Life: 3D Bio-Printed Organs

Explores the groundbreaking world of 3D bioprinting in regenerative medicine, where custom organs printed layer-by-layer from human cells are transforming transplantation. In this video, we uncover the latest advances in bioprinting technology, from biocompatible bioinks to vascularized tissue scaffolds that mimic natural organ architecture.

Dive into the science behind printing life as we showcase flagship projects: a beating mini heart engineered with human cardiomyocytes; 3D-printed liver organoids that perform metabolic functions; and personalized kidney scaffolds seeded with patient-derived stem cells. Learn how bio-printed skin grafts with integrated blood vessels accelerate wound healing and reduce scarring and discover innovations in printing complex structures like pancreas and lung tissue.

We break down key techniques—extrusion-based bioprinting, stereolithographic printing, and sacrificial ink methods—that enable high-resolution, cell-friendly constructs. Our experts explain challenges in tissue vascularization, bioink formulation, and regulatory pathways for clinical use. Gain insights into clinical trials driving the future of organ transplants without donor shortages.

Whether you’re a biotech researcher or tech enthusiast, this video offers insights and case studies. Don’t miss this cutting-edge guide to 3D bio-printed organs and tissue engineering.

#techforgood #futureofmedicine #aiinhealthcare #medicalai #bioprinting #tissueengineering #explainervideo #scienceexplained